ATOS - CIK 0001488039
ATOSSA THERAPEUTICS, INC. (ATOS) reported net income of -$34.77M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$34.77M | -36.3% |
| FY 2024 | -$25.50M | +15.3% |
| FY 2023 | -$30.09M | -11.6% |
| FY 2022 | -$26.96M | -30.8% |
| FY 2021 | -$20.61M | -15.6% |
| FY 2020 | -$17.83M | -3.4% |
| FY 2019 | -$17.24M | -51.2% |
| FY 2018 | -$11.40M | -40.4% |
| FY 2017 |
ATOSSA THERAPEUTICS, INC. (ATOS) reported net income of -$34.77M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ATOSSA THERAPEUTICS, INC.'s net income declined from -$3.44M to -$34.77M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$8.12M |
| -27.5% |
| FY 2016 | -$6.37M | +59.6% |
| FY 2015 | -$15.76M | -7.5% |
| FY 2014 | -$14.66M | -35.9% |
| FY 2013 | -$10.78M | -112.3% |
| FY 2012 | -$5.08M | -47.6% |
| FY 2011 | -$3.44M | - |